Compounded semaglutide: safe and legal?

Compounded semaglutide became widely available during 2023 and 2024 because injectable semaglutide was on the FDA drug shortage list. While a drug is in shortage, compounding pharmacies (under section 503A) and outsourcing facilities (under section 503B) can, within limits, make versions of it. That window is what allowed compounded semaglutide to proliferate, and it is also what has now largely closed.

The honest framing: compounded semaglutide is not an FDA-approved product. Compounded drugs do not go through the FDA review for safety, effectiveness, and quality that approved drugs do.^[1] The approved, studied options are the manufacturer products such as Ozempic and Wegovy. This page explains the regulatory and safety picture; it is not a recommendation to use compounded versions.

Why compounded semaglutide spread

Section 503A lets a state-licensed pharmacy compound for an individual patient based on a prescription, and section 503B lets outsourcing facilities compound, but both restrict making products that are essentially a copy of a commercially available drug. A drug on the FDA shortage list is treated differently, which is what created room for compounded semaglutide during the shortage.^[2] Demand for weight management far outstripped supply, and compounded versions filled the gap, often sold through telehealth channels.

What the FDA warned about

During this period the FDA flagged several safety concerns. It received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide: patients measuring and self-administering incorrect doses, and in some cases health care professionals miscalculating doses.^[1] It also received adverse event reports tied to doses beyond the approved label, including more product per dose, more frequent dosing, or faster titration.^[1]

The salt-form problem

A distinct concern is the active ingredient itself. The FDA is aware that some compounded products used salt forms, including semaglutide sodium and semaglutide acetate. The agency states these salt forms are different active ingredients than are used in the approved drugs, that it does not have information on whether they share the same chemical and pharmacologic properties as the approved active ingredient, and that it is not aware of any lawful basis for their use in compounding.^[1] In other words, a product labeled semaglutide may not contain the same molecule that was actually studied and approved.

The compounded semaglutide timeline and status. Treat each row as regulatory fact, not as a judgment that any individual product is safe.

What changed after the shortage ended

On February 21, 2025 the FDA determined the semaglutide injection shortage was resolved, after confirming the manufacturer could meet present and projected national demand.^[2] To avoid abruptly disrupting patient treatment, the agency set short wind-down windows: it did not intend to act against 503A pharmacies until April 22, 2025 (60 days), or against 503B outsourcing facilities until May 22, 2025 (90 days), for products that are essentially a copy of the approved drug.^[2] Once those windows passed, the broad legal basis for compounding semaglutide as a copy of the approved product ended.

The regulated alternative

The approved products, such as Ozempic and Wegovy, are the versions that went through the FDA review for safety, effectiveness, and quality and that carry studied dosing and titration schedules. Compounding can remain appropriate in narrow situations where a patient's medical need cannot be met by an approved drug, but it is not a routine, equivalent substitute, and it is not the safer or cheaper version it is sometimes marketed as.^[1,2]

Compounded semaglutide filled a shortage. With the shortage resolved, the question is no longer can you get it, but should the approved, studied product be used instead.- Section synthesis